U.S.-South Africa Program for Collaborative Biomedical Research (U01)
The purpose the U.S.-South African Program for Collaborative Biomedical Research is to support research collaborations among U.S. and South African scientists. Research areas supported under this program include TB, HIV/AIDS biomedical and behavioral science, and HIV-related co-morbidities, including malignancies. These funding opportunities are specifically designed to promote partnerships between eligible U.S. extramural investigators (RFA-AI-14-009; RFA-AI-14-010) and eligible South African investigators or eligible U.S. NIH intramural investigators (RFA-AI-14-018) and eligible South African investigators.
Indo-US Collaborative Program on Affordable Medical Devices (R03)
This Funding Opportunity Announcement (FOA) encourages Small Research Grant (R03) applications for its Collaborative Program on Affordable Medical Devices. The Republic of India and the United States of America invite collaborative research projects involving U.S. and Indian investigators to develop new, affordable medical devices for lower resource settings. This FOA will support Small Research Grants to U.S. investigators to develop appropriate diagnostic and therapeutic medical technologies for lower resource settings, and enable product development and/or technology transfer of appropriate technologies. Appropriate medical technologies are those that are useable, cost effective, sustainable, and effective in meeting a significant clinical need in a lower resource setting. Collaborations between U.S. and Indian investigators should be aimed at developing medical technologies that can significantly impact underserved populations within the United States and/or India.
Cancer Detection, Diagnosis, and Treatment Technologies for Global Health (UH2/UH3)
CGH is supporting the development and validation of technologies with the potential to increase early detection, diagnosis, and non-invasive or minimally invasive treatment of cancer. Of particular emphasis is the development of low-cost, portable, point-of-care technologies for resource-constrained settings. The NCI has released a funding opportunity to support the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs). The NCI Board of Scientific Advisors approved three award cycles for this program; however, the NCI must confirm annually that sufficient funds are available to support each possible reissuance.
For more information contact: NCIGlobalHealthTech@mail.nih.gov